摘要
1 免疫治疗 近年来，免疫治疗在肿瘤治疗中由默默无闻到大放异彩，经历了漫长的过程。免疫治疗抗体，抗肿瘤细胞免疫治疗足其蕈要的部分。抗CTLA-4、PD-1／PD-L1抗体作为首当其中的先驱，在黑色素瘤、肺癌、肾痛的临床研究及基础研究中给出了不错的答案，且二者联用取得了更优的结果。
出处
《中国医师杂志》
CAS
2015年第6期801-802,共2页
Journal of Chinese Physician
同被引文献17
-
1韩广玮,申雪晴,谢辉忠,等.124例肾癌诊治体会[J].中国医师杂志,2010,12增刊2:66-67.
-
2Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed interven- tion and surveillance for small renal masses: the DISSRM registry [J[. Eur Urol, 2015, 68(3) : 408-415. DOI: 10. 1016/j. euru- ro. 2015.02. 001.
-
3Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cTl renal masses [ J ]. Eur Urol, 2015, 67 (2) : 252-259. DOI: 10. 1016/j. eururo. 2014.07. 021.
-
4Volpe A, Kachura JR, Geddie WR, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and corebiopsy[J]. J Urol, 2007, 178(2): 379-386. DOI: 10. 1016/j. juro. 2007.03. 131.
-
5Volpe A, Jewett MA. Current role, techniques and outcomes of percutaneous biopsy of renal tumors [ J ]. Expert Rev Anticancer Ther, 2009, 9(6) : 773-783. DOI: 10. 1586/era. 09.48.
-
6Shannon BA, Cohen RJ, de Bruto H, et al. The value of preoper- ative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses[ J] J Urol, 2008, 180 (4) : 1257-1261 ; discussion 1261. DOI: 10. 1016/j. juro. 2008. 06. 030.
-
7Weiss W, Gillick JS. The metastatic spread of bronchogenic carci- noma in relation to the interval between resection and death [ J]. Chest, 1977, 71 (6): 725-729. DOI: 10. 1378/chest. 71.6. 725.
-
8Rybicki FJ, Shu KM, Cibas ES, et al. Percutaneous biopsy of re- nal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses [J]. A JR Am J Roentgenol, 2003, 180 (5): 1281-1287. DOI: 10. 2214/. 180. 5. 1801281.
-
9Silverman SG, Israel GM, Herts BR, et al. Management of the in- cidental renal mass[J]. Radiology, 2008, 249( 1 ) : 16-31. DOI: 10.1148/radiol. 2491070783.
-
10Heuer R, Gill IS, Guazzoni G, et al. A critical analysis of the ac- tual role of minimally invasive surgery and active surveillance for kidney cancer[J]. Eur Urol, 2010, 57(2) : 223-232. DOI: 10. lO16/j, eururo. 2009.10. 023.
-
1Alisa Opar,梁伟.生物标记物在ASCO大放异彩[J].中国处方药,2008,7(7):85-86.
-
2罗利琼,陆幸妍,林月霞,胡丽彩,吴涛.抗CTLA-4单抗阻断肿瘤免疫抑制的研究[J].广东药学院学报,2003,19(1):51-52.
-
3逯云山,翟鹏君,张雪峰,杨海龙,杨原.同期双原发胃癌和肾癌一例[J].中华胃肠外科杂志,2005,8(1):28-28. 被引量：1
-
4陈双瑜,蒋冠,刘彦群,魏志平.抗CTLA-4单克隆抗体治疗黑素瘤的进展[J].国际皮肤性病学杂志,2012,38(2):84-86.
-
5李建华,朱迎,杨菁,钦伦秀.肿瘤免疫检查点靶向治疗的研究进展[J].复旦学报（医学版）,2016,43(1):110-114. 被引量：3
-
6田军,李长岭.肾癌的微创治疗现状与进展[J].癌症进展,2007,5(6):536-539. 被引量：1
-
7B超双重造影术在世界超声联合大会上大放异彩[J].中国医院院长,2009(22):86-86.
-
8许三雄,许建波,张晋煜.进展期恶性黑色素瘤侵袭和转移相关基因研究进展[J].现代肿瘤医学,2012,20(3):651-654. 被引量：5
-
9郭军.恶性黑色素瘤治疗的新进展[J].临床肿瘤学杂志,2007,12(12):881-884. 被引量：25
-
10叶雄俊,林桂亭,常智杰,张志文,辛殿祺,王晓峰,郭应禄.T细胞因子4显性负调节基因ΔNTCF4对肾癌细胞GRC-Ⅰ生物学性状的影响[J].中华泌尿外科杂志,2006,27(12):804-807. 被引量：1
